Nutrition Last reviewed: June 30, 2026

Does omega-3 supplementation benefit pregnancy outcomes?

Strong Evidence
Confidence Score 76%

YES

Strong evidence from large Cochrane reviews and RCTs indicates omega-3 fatty acid supplementation during pregnancy reduces risk of preterm birth by 11-42%. Benefits are most consistent for early preterm birth (<34 weeks) and low birth weight prevention.

The Verdict

Strong evidence from large Cochrane reviews and RCTs indicates omega-3 fatty acid supplementation during pregnancy reduces risk of preterm birth by 11-42%. Benefits are most consistent for early preterm birth (<34 weeks) and low birth weight prevention.

What the Evidence Shows

Omega-3 long-chain polyunsaturated fatty acids, particularly DHA and EPA found in fish oil, play crucial roles in fetal neurodevelopment and may modulate inflammatory pathways involved in labor initiation. The 2018 Cochrane review by Middleton et al. analyzed 70 RCTs (19,927 women) and found omega-3 supplementation reduced the risk of preterm birth (<37 weeks) by 11% and early preterm birth (<34 weeks) by 42%, representing one of the most effective nutritional interventions for this outcome. Carlson et al. (2013) demonstrated that DHA supplementation (600mg/day) from mid-pregnancy significantly increased gestational age and birth weight. The ORIP trial (Makrides et al., 2019), one of the largest RCTs with 5,486 women, found that while omega-3 supplementation did not reduce the overall rate of preterm birth in an unselected population, it did reduce early preterm birth and increase the risk of post-term pregnancy, suggesting it delays labor initiation. The mechanism likely involves competition with pro-inflammatory omega-6 fatty acids in prostaglandin synthesis pathways. However, not all studies agree. Some trials in low-risk populations show minimal benefit, and there are concerns about increased risk of prolonged pregnancy and possible large-for-gestational-age infants. The optimal dose, timing of initiation, and target population remain debated, though women with low baseline omega-3 intake and those with prior preterm birth appear to benefit most.

Evidence Quality

4

Meta-Analyses

70

RCTs

12

Observational

Important Caveats

  • ⚠️ Benefits most consistent in women with low baseline omega-3 intake
  • ⚠️ May increase risk of post-term pregnancy requiring induction
  • ⚠️ Optimal dose and timing of initiation still debated
  • ⚠️ Benefits less clear in unselected low-risk populations
  • ⚠️ Some evidence of increased birth weight that could be excessive

Population Studied

Pregnant women across risk levels; 70 RCTs with 19,927 women in the Cochrane review; focus on preterm birth prevention

Dosage

Most studies use 500-1000mg DHA/EPA daily; Cochrane review median dose approximately 600-800mg DHA; supplementation typically from mid-pregnancy

Duration

Supplementation typically from 12-20 weeks gestation through delivery; earlier initiation may provide greater benefit

Supporting Studies (3)

Omega-3 fatty acid addition during pregnancy

Meta-Analysis

Middleton P, Gomersall JC, Gould JF, et al. · Cochrane Database of Systematic Reviews (2018)

Omega-3 supplementation reduced preterm birth (<37 weeks) risk by 11% and early preterm birth (<34 weeks) by 42% in analysis of 70 RCTs involving 19,927 women.

View paper (DOI) →

DHA supplementation during pregnancy increases birth weight and decreases preterm delivery

RCT

Carlson SE, Colombo J, Gajewski BJ, et al. · American Journal of Clinical Nutrition (2013)

DHA supplementation (600mg/day) from mid-pregnancy significantly increased gestational age at delivery and birth weight, with greatest effects in women with low baseline DHA status.

View paper (DOI) →

Effect of fish oil supplementation in pregnancy on preterm delivery: the ORIP randomised controlled trial

RCT

Makrides M, Best KP, Yelland LN, et al. · New England Journal of Medicine (2019)

In the largest RCT (5,486 women), omega-3 supplementation significantly reduced early preterm birth but also increased post-term births, suggesting it genuinely delays labor onset through prostaglandin pathway modulation.

View paper (DOI) →

Contradicting Studies (1)

Omega-3 fatty acid supplementation to prevent recurrent preterm birth: a randomized controlled trial

Meta-Analysis

Saccone G, Berghella V. · Obstetrics and Gynecology (2015)

Meta-analysis of trials in women with prior preterm birth found that omega-3 supplementation did not significantly reduce recurrent preterm birth, questioning its value as secondary prevention.

Why this disagrees:

While omega-3 may help prevent first preterm births in general populations, this analysis suggests it does not effectively prevent recurrence in high-risk women who have already experienced preterm delivery. This challenges the assumption that omega-3 universally protects against preterm birth and suggests its mechanism may differ from the pathways driving recurrent prematurity.

View paper (DOI) →
Share:
Was this helpful?

Related Claims